Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Edward Chambers
e.chambers@imperial.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Propionate and bone health
Back

Propionate and bone health

Recruiting

Open to: Female

Age: Adult

London

Medical Conditions

Prevention of osteoporotic fractures in postmenopausal women

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Osteoporotic fractures are a major health issue in the UK, with over 500,000 cases each year. Postmenopausal women are at a higher risk due to the impact of menopause on bone health. This study aims to test a new dietary supplement called inulin-propionate ester (IPE) to see if it can improve bone health and prevent fractures in postmenopausal women.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

01 Jun 2025 31 May 2026

Participants will attend four visits at the NIHR Imperial Clinical Research Facility at Hammersmith Hospital. These visits include health screenings, blood and urine tests, and dietary assessments. Participants will take either the IPE supplement or a control substance daily for 8 weeks. Blood and stool samples will be collected regularly to measure health markers.


Postmenopausal women aged 50-75 years.

You can take part if:



You may not be able to take part if:


1. Weight change of ≥ 3kg in the preceding 2 months2. Current smokers3. Substance abuse4. Excess alcohol intake5. Cardiovascular disease6. Cancer 7. Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome8. Kidney disease9.Pancreatitis10. Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • NIHR Imperial Clinical Research Facility
    Hammersmith Hospital Du Cane Rd Shepherd's Bush
    London
    W12 0HS

Participants may benefit from learning more about their health. However, there are some risks, such as mild discomfort from blood tests and potential side effects from the supplement, like bloating and flatulence. Any health issues discovered during the study will be communicated to the participant and their GP.

Dr Edward Chambers
e.chambers@imperial.ac.uk



The study is sponsored by Imperial College London and funded by Rosetrees Trust; Stoneygate Trust.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN10449148
Last updated 09 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top